Combined Modality Treatment of Limited Stage Small Cell Carcinoma of the Lung

Author(s): Don Yee, Brita Danielson, Wilson Roa

Journal Name: Reviews on Recent Clinical Trials

Volume 3 , Issue 2 , 2008

Become EABM
Become Reviewer
Call for Editor


Small cell lung carcinoma comprises approximately 10-20% of all lung cancers. At the time of diagnosis, 20-30% of patients have what is considered limited stage disease. Historically, chemotherapy has been the mainstay of treatment for small cell lung cancer, but more recent evidence from large meta-analyses have established the local control and overall survival advantages conferred by the addition of external beam thoracic radiotherapy in combination with chemotherapy for limited stage disease along with prophylactic cranial irradiation for complete responders. At present, radiotherapy is recommended to commence in concurrentoe with an earlier cycle of chemotherapy. Despite the established role of thoracic radiotherapy combined with chemotherapy for patients with limited stage disease, the optimal radiotherapy dose-fractionation schedule is still undefined. Recent investigational radiotherapy approaches applied to limited stage small cell lung cancer patients include hyperfractionated radiotherapy, dose-escalated daily radiotherapy, and hypofractionation. While several chemotherapy regimens and targeted systemic agents have been investigated in small numbers of small cell lung cancer patients, cisplatin with etoposide remains the current standard chemotherapy regimen for this cancer.

Keywords: Small cell lung cancer, combined modality therapy, chemoradiotherapy

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [150 - 155]
Pages: 6
DOI: 10.2174/157488708784223880
Price: $65

Article Metrics

PDF: 3